According to the hormonal receptor status, BC patients were classified into luminal A (ER/PR+, HER2−; 8/80 (10%)), luminal B (ER/PR+, HER2+; 52/80 (65%)), and triple negative (ER−/PR−/HER2−; 20/80 (25%)). Here, ERBB2 is linked to breast cancer.